SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

All You Need is the One System Solution

FOR ALL ARRHYTHMIAS AND ABLATIONS

One System Solution

PFA Visualization on EnSite™ X EP System Supported by Abbott's Expert Clinical Specialists

The right system for your procedures is the one that allows you to treat AFib your way for optimal outcomes, safety and efficiency.

Abbott gives you more opportunities to choose the course of treatment and workflow that’s right for your patients, because #MappingMatters. EnSite™ X EP System - THE INDUSTRY’S ONLY OPEN ARCHITECTURE DESIGN - is the only system to offer a comprehensive solution for RF and PFA procedures – from mapping to outcomes.

Map to Reduce Radiation and Elevate Safety

Every patient deserves 3D mapping to increase navigation accuracy, reduce radiation risk, optimize workflow, and potentially improve outcomes in mapping PVI and beyond.

3D mapping with Ensite X EP System

RADIATION RISK DURING EP PROCEDURES

radiation exposure during ep procedures
conventional vs fluoroless procedure

NEARLY ZERO RADIATION WITH ENSITE™ X EP SYSTEM

EnSite™ X EP System stands alone as the only open architecture mapping system capable of driving fluoroscopy exposure to nearly zero1 with its combination of 3D mapping, PFA visualization and lowest radiation exposure ablation times3.

Nearly zero radiation with Ensite XP

PFA visualization with EnSite™ X EP System may reduce fluoroscopy times during PFA procedures.

EnSite™ X EP System with TactiFlex™ Ablation Catheter, Sensor Enabled™ has the lowest radiation3 exposure time compared to other technologies in the market, proven by the TactiFlex IDE trial.

reduced radiation exposure

Improve Procedural Success Rates For All AF Types. Map Beyond PVI.

EnSite™ X EP System provides the mapping flexibility, detail and real-time technology vital for low-voltage area ablation procedures. Map beyond PVI to identify, target and ablate cardiac tissue with specificity for acute and long-term outcomes. Patients undergoing 3D mapping-guided low-voltage area are experiencing greater freedom from paroxysmal and persistent AF.

EnSite X EP system mapping
EnSite X EP system real time technology

SIGNIFICANTLY REDUCE ATRIAL TACHYARRHYTHMIA RECURRENCE WITH 3D MAPPING-GUIDED LOW-VOLTAGE AREA THERAPY9

Fewer atrial tachyarrhythmia recurrences9

down arrow

Lower number of redo ablation procedures9

down arrow

Similar results for all AF types – paroxysmal, persistent and long-standing persistent AF9

checkmark

IMPROVE LONG-TERM OUTCOMES IN OLDER PATIENTS WITH PAROXYSMAL AF3

39% lower rate of recurrence for patients with persistent AF undergoing PVI with substrate modification vs PVI only (35% vs. 50%)10

2-3 year improved outcomes; differentiation in patient populations noted at 1 year3

down arrow

REDUCE ATRIAL ARRHYTHMIA RECURRENCE RATES AND AVOID OVERABLATION10

 

15% lower rate of recurrence for patients with persistent AF undergoing PVI with substrate modification vs PVI only (35% vs. 50%)10

down arrow

TAILOR ABLATION STRATEGIES TO PROMOTE BETTER ACUTE AND LONG-TERM CLINICAL OUTCOMES FOR PERSISTENT AF11

PATIENTS UNDERGOING CIRCUMFERENTIAL PV ABLATION11:

Ablation mapping chart

50% Improved acute intraprocedural arrhythmia termination11

Increase

13% Higher procedural success rates11

Increase
One System Solution Products
One System Solution Products

CREATE EFFICIENCIES. MAP TO OPTIMIZE WORKFLOW.

One System Solution: the only open architecture design that gives you full flexibility to treat AFib your way.

One System Solution Products
Dig Into The Data

*The EnSite™ X EP System has an open architecture which is capable of providing impedance based visualization for any catheter, which can be connected the the system via direct connection or with pins using the catheter input module.
 

These devices are commercially available for use in select international markets.

    REFERENCES:

    1. Fiorenzo Gaita, Peter G. Guerra. Alberto Battaglia, Matteo Anselmino (2016). The Dream of near-zero X-Rays ablation comes True. European Heart Journal, Volume 37, Issue 36, 21 September 2016.
    2. Nair, D., Martinek, M., Colley, B. J., Sundaram, S., Hariharan, R., Morales, G., ... & Lo, M. (2023). Safety and effectiveness of the first contact force ablation catheter with a flexible tip. Heart Rhythm O2, 4(12), 784-793.
    3. Chen, H. et al. (2023). Circumferential pulmonary vein isolation with vs without additional low-voltage-area ablation in older patients with paroxysmal atrial fibrillation. JAMA Cardiology, 8(8), 765. https://doi.org/10.1001/jamacardio.2023.1749.
    4. Jose Osorio, Gustavo Morales, Michael Raiman (2023) High Efficiency Workflow During Atrial Fibrillation Ablation: Protocol and Experience with EnSite X Mapping System, July 2023, Vol.16 Issue 5.
    5. Osorio, J., Hussein, A. A., Delaughter, M. C., Monir, G., Natale, A., Dukkipati, S., ... & Q-FFICIENCY Trial Investigators. (2023). Very high-power short-duration, temperature-controlled radiofrequency ablation in paroxysmal atrial fibrillation: the prospective multicenter Q-FFICIENCY trial. Clinical Electrophysiology, 9(4), 468-480.
    6. Mohit K. Turagam , MD; Petr Neuzil , MD PhD; Boris Schmidt , MD; Tobias Reichlin , MD; Kars Neven, MD; Andreas Metzner, MD; Jim Hansen, MD; Yuri Blaauw, MD…… Philippe Maury,MD (2023) Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry. Circulation. 2023;148:35–46. DOI: 10.1161/CIRCULATIONAHA.123.064959.
    7. Reddy, V. Y., Gerstenfeld, E. P., Natale, A., Whang, W., Cuoco, F. A., Patel, C., ... & Mansour, M. (2023). Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. New England Journal of Medicine, 389(18), 1660-1671.
    8. Verma, A., Haines, D. E., Boersma, L. V., Sood, N., Natale, A., Marchlinski, F. E., ... & PULSED AF Investigators. (2023). Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation,147(19), 1422-1432.
    9. Rivera, A. et al. (2024). Adjunctive Low-voltage area ablation for patients with atrial fibrillation: An updated meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16290.
    10. Huo, Y. et al. (2022). Low-voltage myocardium-guided ablation trial of persistent atrial fibrillation. NEJM Evidence, 1(11). https://doi.org/10.1056/evidoa2200141.
    11. Pappone, C. et al. (2018). Clinical outcome of electrophysiologically guided ablation for nonparoxysmal atrial fibrillation using a novel real-time 3-dimensional mapping technique. Circulation: Arrhythmia and Electrophysiology, 11(3). https://doi.org/10.1161/circep.117.005904.

    MAT-2414289 v1.0

    POLICIES & ADVISORIES
    HEALTHCARE PROFESSIONALS
    PATIENTS & CAREGIVERS
    Abbott logo

    Information contained herein for distribution outside the U.S. only.

    CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

    Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

    Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

    © 2025 Abbott. All Rights Reserved.

    MAT-2001111 v8.0

    Disclaimer

    You are about to enter an Abbott country- or region-specific website. 

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

    Do you wish to continue and enter this website? 

    YES

    MAT-2305078 v1.0